Therapix Bioscience, Ltd. (NASDAQ: TRPX) Jumps 40% After LOI to Merge with Destiny Biosciences Global Corp.

Therapix Bioscience, Ltd. (NASDAQ: TRPX) operates as a clinical-stage pharmaceutical company, which is focused on developing a pipeline and assets based on cannabinoid-based pharmaceutical treatments. The Israeli cannabis pharma developer currently has tetrahydrocannabinol- (THC) and CannAmide-based drug development programs. Shares of the cannabinoid pharmaceutical developer are jumping 40%, through afternoon trading on Tuesday, July 23, 2019. Over the past three…

Read More

Which Pot Stock Should You Buy: Aphria Inc (TSX:APHA) or Green Organic Dutchman Holdings Ltd (TSX:TGOD)?

If you invested in a cannabis company last year, you likely made an impressive return. As the stock market caught up to the rapidly growing marijuana industry, nearly every pot stock rose considerably. Today, nearly a dozen cannabis stocks have market valuations in excess of $1 billion. In many ways, the incredible bargains of yesterday are gone. To succeed as…

Read More

Q BioMed Announces Strategic Partnership with SRI International for Formulation and Preclinical Development of QBM-001 for Pediatric Nonverbal Disorder in Autistic Children

Collaboration with SRI Provides QBioMed Expertise in Formulation Development and Preclinical Work in Autism, as well as CMC and Manufacturing capability NEW YORK, December 12, 2018 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce a collaborative agreement with SRI International to provide formulation development, preclinical development, and early clinical manufacturing of QBM-001, in support…

Read More